BeiGene

China's largest global biotech company focused on innovative oncology medicines

Company Overview

BeiGene is a global biotechnology company headquartered in China that is focused on developing innovative and affordable medicines for cancer patients worldwide. The company's BTK inhibitor Brukinsa has become one of the best-selling cancer drugs globally, and BeiGene has built a commercial presence in over 40 countries. BeiGene represents China's most successful biotech globalization story.

Sectors

OncologyImmunologyHematology

Primary Markets

ChinaUSEuropeGlobal

Why This Company Matters

BeiGene has shattered the perception that Chinese biotech companies cannot compete globally, with Brukinsa becoming a blockbuster drug in the US and European markets.

Key Focus Areas

OncologyHematologyImmunologyGlobal Commercialization

Peer Companies

View all

Biocon

1 signals

India's largest biopharmaceutical company and global biosimilars leader

Bangalore, India

Celltrion

0 signals

South Korea's leading biosimilar manufacturer challenging global pharma giants

Incheon, South Korea

Daiichi Sankyo

0 signals

Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)

Tokyo, Japan

Doctor Anywhere

0 signals

Southeast Asia's leading omnichannel healthcare platform

Singapore

Halodoc

1 signals

Indonesia's leading telehealth and health-tech platform

Jakarta, Indonesia

Healius

0 signals

Australia's second-largest private pathology and imaging provider

Sydney, Australia

Signal Activity

0This Month

1Last 30 Days

1Total

Signal Timeline

1 total

February 2026

RegulatoryCanonicalFeb 12

BeiGene's PD-1 Inhibitor Tislelizumab Approved in Japan, Challenging Global Pharma Giants

BeiGene's anti-PD-1 antibody tislelizumab has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of non-small cell lung cancer. This marks a significant milestone as a Chinese-developed immunotherapy gains approval in one of the world's most stringent regulatory markets, directly competing with Merck's Keytruda and Bristol-Myers Squibb's Opdivo.

Get BeiGene signal updates

Get notified when new signals are published for this company.